AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Los Angeles, March 12, 2021 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 21, 2020 and November 20, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before March 29, 2021.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AstraZeneca PLC and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

"Just because it's reported following a vaccination doesn't mean that it's because of the vaccination," WHO's chief scientist Dr. Soumya Swaminathan said.

WHO says it's investigating reports of blood clots in people who got AstraZeneca Covid vaccine

The World Health Organization said countries should not stop using AstraZeneca's COVID-19 vaccine amid fears about people who received the jab developing blood clots. In a Friday briefing, WHO spokesperson Margaret Harris said no causal link had been established between the British drugmaker's “excellent” shot and the blood clot cases that have emerged in Europe.

WHO says AstraZeneca COVID vaccine OK to use despite blood clot fears

Europe's COVID-19 vaccine rollout with AstraZeneca Plc (NASDAQ: AZN) has intensified further, with at least nine countries suspending the use of the shot over safety concerns, reports Bloomberg. This latest concern comes on top of the company's already existing supply problem with the EU.

Europe's Vaccination Drive Shaky As Bloc Grapples With Safety Scare Related To AstraZeneca COVID-19 Shot: Report

Thailand delayed the shot's rollout over fears it causes blood clots, despite assurances from regulators that there is no evidence linking the vaccine to the incidents.

Experts Defend Safety Of AstraZeneca Covid-19 Vaccine After Several Countries Suspend The Shot

The European Union has asked AstraZeneca to do more to respect its contract with the bloc, as concerns grow that the firm will miss delivery targets once again.

EU says AstraZeneca is not doing enough to meet its vaccine deliveries target

AstraZeneca has said the vaccine has been studied extensively during Phase 3 trials and peer-reviewed data confirms the shot is "generally well tolerated."

More countries suspend AstraZeneca vaccinations over blood clot fears: What we know so far

Thailand said Friday it had paused use of AstraZeneca's COVID-19 vaccine while investigators looked into potential side effects and adverse reactions, becoming the first Asian country to make the move. Denmark, Norway, and Iceland all said on Thursday they were suspending all use of the vaccine following several cases of blood clots among vaccinated people. Several other European countries, including Italy, have suspended a specific batch of the vaccine.

Thailand follows Denmark in suspending AstraZeneca's COVID-19 vaccine, pending an investigation into possible side effects

Six European countries have temporarily halted distribution of AstraZeneca PLC's (LON:AZN) Covid-19 vaccine due to concern over possible side effects. Denmark today followed Austria, Estonia, Latvia, Lithuania and Luxembourg in pausing the use of a 1mln-dose batch sent to a total of 17 countries within the EU.

AstraZeneca vaccine suspended in Denmark over side effect concerns

The shares of AstraZeneca PLC (NASDAQ:AZN) are down 1.7% to trade at $48.95 this morning, following news that Italy banned the drugmaker's Covid-19 vaccine after two recently inoculated men died in Sicily.

European Pause on AstraZeneca Vaccine Sends Stock Lower

Los Angeles, California--(Newsfile Corp. - March 11, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between May 21, 2020 and November 20, 2020, inclusive...

INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AstraZeneca PLC and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Today, Denmark said it was suspending its use of the Oxford/AstraZeneca vaccine while it was investigating several cases of blood clots among people who had received the jab. Norway followed a few hours later. Let's be clear. To date, all signs point towards AstraZeneca's vaccine working and being safe. Multiple respected regulators cleared it for us, and millions of people have had the shot.

Denmark suspending use of the AstraZeneca COVID-19 jab is another dark cloud over a troubled vaccine

Earlier this week the European drug regulator had said there was no indication that the vaccine caused blood clotting.

Denmark, Norway Pause Rollout Of AstraZeneca Vaccine Over Blood Clotting Concerns

Denmark's health authority said it cannot be concluded whether there is a link between the vaccine and the blood clots.

AstraZeneca Shares Fall as Denmark Pauses Shots of Its Covid-19 Vaccine Following Blood Clots

Denmark's national health agency temporarily suspends inoculations with the AstraZeneca Plc (NASDAQ: AZN) COVID-19 shot after blood clots formed in several people who had the jab, one of whom has reportedly died, reports CNBC. Søren Brostrøm, director of the National Board of Health in Denmark, insisted that the 14-day suspension was a precaution while investigations took place.

Denmark Stops Use Of AstraZeneca COVID-19 Shot Over Blood Clot Fears: CNBC

Denmark has announced that it is to temporarily suspend the use of the coronavirus vaccine developed by AstraZeneca and the University of Oxford.

Denmark suspends use of AstraZeneca vaccine over reports of blood clots

Denmark has stopped using AstraZeneca's COVID-19 vaccine because of potential serious side effects. The country has halted use of the vaccine after several cases of blood clots among vaccinated people, the Danish health authority said.

Denmark suspended the use of AstraZeneca's COVID-19 vaccine, citing the risk of blood clots

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the "Class Period"), of the important March 29, 2021 lead plaintiff deadline. SO WHAT: If you purchased AstraZeneca securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEX

ROSEN, A LEADING LAW FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline – AZN

New York, New York--(Newsfile Corp. - March 8, 2021) - WHY:  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the "Class Period"), of the important March 29, 2021 lead plaintiff deadline.SO WHAT: If you purchased AstraZeneca securities during the Class Period you may be entitled to compensation without payment of any out of pocket...

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline - AZN

Italy joins France and Germany in reversing its stance, giving green light for use of the shot in older people.

Italy approves AstraZeneca's COVID-19 vaccine for over 65s

South Korea is one of several countries to investigate the link between the Oxford-AstraZeneca shot and adverse reactions after vaccination.

South Korean Probe Finds No Link Between AstraZeneca Covid-19 Vaccine And Deaths

Moderna

Pfizer

BioNTech SE

CureVac B.V

Johnson & Johnson

Novavax

Sinovac Biotech

The companies in line for the biggest gains – and the shareholders who have already made fortunes

From Pfizer to Moderna: who's making billions from Covid-19 vaccines?

Europe is already vaccinating with AstraZeneca's product.

Why AstraZeneca May Dominate the European Vaccine Market

Boston, Massachusetts--(Newsfile Corp. - March 5, 2021) - The Thornton Law Firm announces that a class action lawsuit has been filed on behalf of investors of AstraZeneca PLC (NASDAQ: AZN). The case is currently in the lead plaintiff stage. Investors who purchased AZN stock or other securities between May 21, 2020 and November 20, 2020 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/AstraZeneca to submit their information. Investors may also email...

AstraZeneca Investor Alert: Class Action Lawsuit Filed

Preliminary data from a study conducted at the University of Oxford suggests that AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine is effective against the P1 or Brazilian variant, reports Reuters. The data indicate that the vaccine will not need modification to protect against the variant.

News for AstraZeneca Stock (AZN)